Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2417773 | 0.89 | MAPT (0.45) | ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL3950967 | 0.88 | PPM1B (0.41) | ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3953036 | 0.85 | ADRB2 (0.36) | ALDH1A1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL6050359 | 0.83 | EPHX2 (0.40) | ALDH1A1MAPTKDM4E | |
| SCHEMBL8827702 | 0.81 | EPHX2 (0.44) | SMN1; SMN2HTT | |
| SCHEMBL4109807 | 0.81 | — | — | |
| SCHEMBL4673128 | 0.79 | SMN1; SMN2 (0.43) | ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL3729246 | 0.79 | SMN1; SMN2 (0.43) | ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL29427 | 0.78 | — | — | |
| SCHEMBL18367 | 0.78 | ALDH1A1 (0.68) | ALDH1A1MEN1KMT2AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1601674-B1 | Hydroxyalkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-08 | — | — | EP | claimed |
| JP-4712384-B2 | — | — | 2011-06-29 | — | — | JP | claimed |
| EP-1740587-A4 | SELECTIVE ANTAGONISTS OF A-2A- ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS LLC (US) | 2009-07-15 | — | — | EP | claimed |
| EP-1865963-A2 | TRIAZADIBENZOAZULENE COMPOUNDS USEFUL FOR THE TREATMENT AND PREVENTION OF PAIN AND SCREENING METHODS THEREFOR | Acadia Pharmaceuticals Inc. (US) | 2007-12-19 | — | — | EP | claimed |
| US-7297796-B2 | Sulfamoyl benzamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2007-11-20 | — | — | US | claimed |
| US-20070191426-A1 | Derivatives of 3-aminocarbonylquinoline, pharmaceutical compositions containing them and processes and intermediates for their preparation | GLAXO GROUP LIMITED (GB) | 2007-08-16 | — | — | US | claimed |
| US-7217702-B2 | Selective antagonists of A2A adenosine receptors | ADENOSINE THERAPEUTICS, LLC (US) | 2007-05-15 | — | — | US | claimed |
| JP-2007506717-A | — | — | 2007-03-22 | — | — | JP | claimed |
| US-20070066614-A1 | Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB | 2007-03-22 | — | — | US | claimed |
| US-7173030-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2007-02-06 | — | — | US | claimed |
| WO-2005030725-A1 | DERIVATIVES OF 3-AMINOCARBONYLQUINOLINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES AND INTERMEDIATES FOR THEIR PREPARATION | GLAXO GROUP LIMITED (GB) | 2005-04-07 | — | — | WO | claimed |
| US-20050009821-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB | 2005-01-13 | — | — | US | claimed |
| WO-2004103980-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I | BIOVITRUM AB (SE) | 2004-12-02 | — | — | WO | claimed |
| US-20040142955-A1 | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1receptor mediated disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-07-22 | — | — | US | claimed |
| WO-2004022558-A2 | HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-03-18 | — | — | WO | claimed |
| US-6515122-B1 | The invention further relates to combinatorial libraries containing two or more such compounds, as well as methods of preparing tetracyclic benzimidazole derivative compounds. | LION BIOSCIENCE AG (DE) | 2003-02-04 | — | — | US | claimed |
| EP-1218384-A4 | TETRACYCLIC BENZIMIDAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2002-11-20 | — | — | EP | claimed |
| EP-1218384-A1 | TETRACYCLIC BENZIMIDAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-07-03 | — | — | EP | claimed |
| WO-2001023392-A1 | TETRACYCLIC BENZIMIDAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-04-05 | — | — | WO | claimed |
| WO-1999062905-A1 | 8-PHENYLXANTHINE DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | ALMIRALL PRODESFARMA, S.A. (ES) | 1999-12-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191426-A1 | Derivatives of 3-aminocarbonylquinoline, pharmaceutical compositions containing them and processes and intermediates for their preparation | PDE4B, PDE4A, PDE3B | ALDH1A1 503/4885MEN1 4369/4885KMT2A 1741/4885 |
| US-20040142955-A1 | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1receptor mediated disorders | OPRL1, GPR4, ADRA1D | ALDH1A1 196/4885MEN1 1837/4885KMT2A 3144/4885 |
| US-20050009821-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD11B2 | ALDH1A1 53/4885MEN1 942/4885KMT2A 3325/4885 |
| US-20070066614-A1 | Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD17B11 | ALDH1A1 36/4885MEN1 974/4885KMT2A 3281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.